| Literature DB >> 31275383 |
Abdul Rashid Adams1, Priscillia Awo Nortey2, Benjamin Ansah Dortey3, Richard Harry Asmah1, Edwin Kwame Wiredu4.
Abstract
Cervical cancer is a largely preventable disease mediated by persistent infection with high-risk Human Papillomaviruses (Hr-HPV). There are now three approved vaccines against the most common HPV genotypes. In Ghana, mortality due to cervical cancer is on the rise, due to the absence of an organized and effective cervical cancer prevention and control program. Data on circulating HPV genotypes is important for studying the likely impact of mass introduction of HPV vaccination of the female population before sexual debut. High HPV prevalence has been reported in Female Sex Workers (FSWs), who constitute an important active group for maintenance of HPV in the population. This study was conducted to determine the size of HPV prevalence in this group and to provide information for future assessment of the impact of vaccine introduction in the country. We conducted a cross-sectional study where the snowballing technique was used to identify and select FSW's ≥18 years, operating within suburbs of Greater Accra Region (GAR). A risk factor assessment interview was conducted and cervical swabs were collected for HPV-DNA detection and genotyping by Nested Multiplex PCR. Hundred participants, age ranging from 18 to 45 years, median 24 years, were studied. The prevalence of Cervical HPV was 26%. Eleven genotypes were detected comprising 9 high-risk in order of decreasing prevalence HPV-16 (8%), HPV-35 (5%), HPV-33/39/-68 (3%), HPV-52/51/59 (2%) and HPV-18 (1%) and 2 Low-risk types, HPV-42(3%), and HPV-43 (1%). Three women had HPV types that could not be genotyped by our method. Oral contraceptives use was associated with a reduced chance of HPV infection (P=0.002; OR=0.19, 95% CI 0.07-0.54). This study found a high HPV prevalence among FSWs in the GAR. A high number of Hr-HPV genotypes seen are vaccine preventable, providing additional compelling argument for implementing a national cervical cancer prevention plan including vaccination.Entities:
Year: 2019 PMID: 31275383 PMCID: PMC6582788 DOI: 10.1155/2019/8062176
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.375
Type-specific HPV prevalence.
| HPV type | Single infections | Multiple | Total (%) |
|---|---|---|---|
|
| |||
|
| |||
| 16 | 4 | 4 | 8(8) |
| 35 | 4 | 1 | 5(5) |
| 33 | 2 | 1 | 3(3) |
| 39 | 3 | 0 | 3(3) |
| 68 | 1 | 2 | 3(3) |
| 51 | 2 | 0 | 2(2) |
| 52 | 1 | 1 | 2(2) |
| 59 | 2 | 0 | 2(2) |
| 18 | 0 | 1 | 1(1) |
|
|
|
|
|
|
| |||
| 42 | 2 | 1 | 3(3) |
| 43 | 0 | 1 | 1(1) |
|
|
|
|
|
|
| |||
| X | 3 | 0 | 3(3) |
|
|
|
|
|
Figure 1Age-specific HPV prevalence.
Cytologic changes in HR-positive individuals.
| Cytology results | HR-Genotypes |
|---|---|
| NILM | 16, 18, 68 |
| NILM | 16,35,68 |
| NILM | 33 |
| NILM | 39 |
| HSIL | 16,33,68 |
| NILM | 52 |
| NILM | 35 |
| NILM | 16 |
| NILM | 16 |
| NILM | 16 |
| NILM | 39 |
| LSIL | 16 |
| LSIL | 35 |
| ASCUS | 51 |
| HSIL | 51 |
| NILM | 35 |
| HSIL | 39 |
| ASCUS | 16,52 |
| NILM | 35 |
| LSIL | 33 |
| NILM | 59 |
| ASCUS | 59 |
Results of univariate logistic regression analysis of risk factors for HPV infection.
| Variables | HPV (+) | HPV (-) | OR (95% CI) | P-value |
|---|---|---|---|---|
|
| ||||
| <25 | 17 | 41 | 0.65 (0.26- 1.67) | 0.38 |
| 25-34 | 3 | 23 | 3.46 (0.9412.67) | 0.06 |
| 35-44 | 6 | 9 | 0.46 (0.15-1.46) | 0.19 |
| 45-54 | 0 | 1 | - | - |
|
| ||||
|
| ||||
| No formal education | 1 | 5 | 1.81 (0.20-16.27) | 0.60 |
| Basic | 18 | 56 | 1.38 (0.52-3.71) | 0.52 |
| Higher | 7 | 13 | 0.59 (0.20-1.66) | 0.31 |
|
| ||||
|
| ||||
| <1 | 6 | 17 | 1.45(0.48-4.38) | 0.51 |
| 1-2 | 6 | 27 | 1.47(0.55-3.94) | 0.46 |
| 3-4 | 6 | 13 | 0.65(0.21-1.94) | 0.44 |
| ≥5 | 8 | 15 | 0.58(0.20-.1.65) | 0.31 |
|
| ||||
|
| ||||
| Yes | 13 | 34 | 0.85 (0.35-2.08) | 0.72 |
|
| ||||
|
| ||||
| ≤14 | 14 | 40 | 1.01 (0.41-2.71) | 0.99 |
| >14 | 12 | 34 | 1.05 (0.43-2.66) | 0.92 |
|
| ||||
|
| ||||
| Condom | 20 | 62 | 1.55 (0.52-4.66) | 0.44 |
| Oral contraceptive | 11 | 9 |
|
|
|
| ||||
|
| ||||
| <16 | 7 | 16 | 0.74 (0.27-2.09) | 0.58 |
| 16-20 | 19 | 55 | 1.07 (0.38-2.93) | 0.90 |
| >20 | 0 | 3 | - | 0.99 |
|
| ||||
|
| ||||
| 0 | 11 | 30 | 0.93 (0.37-2.30) | 0.88 |
| 1-2 | 14 | 36 | 0.81 (0.33-1.99) | 0.65 |
| ≥3 | 1 | 8 | 3.03 (0.36-25.47) | 0.31 |
|
| ||||
|
| ||||
| Current smoking | 7 | 10 | 0.42 (0.14-1.26) | 0.12 |
| Past smoking | 9 | 24 | 0.91 (0.35-2.32) | 0.84 |
|
| ||||
|
| ||||
| Yes | 9 | 14 | 0.44(0.16-1.11) | 0.11 |
|
| ||||
|
| ||||
| Genital warts | 1 | 1 | 0.34(0.02-5.68) | 0.46 |
| Gonorrhoea | 5 | 9 | 0.58(0.12-5.68) | 0.36 |
| Syphilis | 2 | 2 | 0.33(0.04-2.50) | 0.29 |
| Herpes | 1 | 1 | 0.34(0.02-5.68) | 0.46 |
| HIV | 2 | 0 | - | - |